Zometa Label Adds Osteonecrosis Of The Jaw Precaution
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.